1. Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry. Lanham: Rowman & Littlefi eld; 2008.
2. G?tzsche P. C. Bias in double-blind trials (thesis). Dan Med Bull. 1990; 37: 329–36.
3. G?tzsche P. C. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal, antiinflammatory drugs in rheumatoid arthritis. Controlled Clin Trials. 1989; 10: 31–56 (amendment: 356).
4. Bero L. A., Rennie D. Influences on the quality of published drug studies. Int J Tech Assessm Health Care. 1996; 12: 209–37.
5. Safer D. J. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis. 2002; 190: 583–92.
6. Melander H., Ahlqvist-Rastad J., Meijer G., et al. Evidence b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003; 326: 1171–3.
7. McGauran N., Wieseler B., Kreis J., et al. Reporting bias in medical research – a narrative review. Trials. 2010; 11: 37.
8. Boutron I., Dutton S., Ravaud P., et al. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA. 2010; 303: 2058–64.
9. G?tzsche P. C. Meta-analysis of grip strength: most common, but superfluous variable in comparative NSAID trials. Dan Med Bull. 1989; 36: 493–5.
10. G?tzsche P. C. Patients’ preference in indomethacin trials: an overview. Lancet. 1989; i: 88–91.
11. Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.
12. Bero L., Oostvogel F., Bacchetti P., et al. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med. 2007; 4: e184.
13. Kelley C., Helfand M., Good C., et al. Drug class review. Hydroxymehylglutaryl-coenzyme A reductase inhibitors (statins). 2002 Dec. Available online at: www.pbm.va.gov/reviews/hmgstatins04-09-03.pdf (accessed 11 November 2012).
14. Lundh A., Sismondo S., Lexchin J., et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012; 12: MR000033.
15. Heres S., Davis J., Maino K., et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006; 163: 185–94.
16. Moffatt B., Elliott C. Ghost marketing. Perspect Biol Med. 2007; 50: 18–31.
17. Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy. 2007 July: 991–1012.
18. Healy D., Cattell D. Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry. 2003; 183: 22–7.
19. Sismondo S., Nicholson S. H. Publication planning 101: a report. J Pharm Pharmaceut Sci. 2009; 12: 273–9.
20. G?tzsche P. C., Hrybjartsson A., Johansen H. K., et al. Ghost authorship in industry-initiated randomized trials. PLoS Med. 2007; 4: e19.
21. Yank V., Rennie D. Disclosure of researcher contributions: a study of original research articles in The Lancet. Ann Intern Med. 1999; 130: 661–70.
22. Flanagin A., Carey L. A., Fontanarosa P. B., et al. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA. 1998; 280: 222–4.
23. Healy D. Shaping the intimate: influences on the experience of everyday nerves. Soc Stud Sci. 2004; 34: 219–45.
24. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
25. Zuger A. How tightly do ties between doctor and drug company bind? New York Times. 2004 June 27.
26. Avorn J., Chen M., Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982; 73: 4–8.
27. Prosser H., Almond S., Walley T. Influences on GPs’ decision to prescribe new drugs – the importance of who says what. Fam Pract. 2003; 20: 61–8.
28. Henry D., Doran E., Kerridge I., et al. Ties that bind: multiple relationships between clinical researchers and the pharmaceutical industry. Arch Intern Med. 2005; 165: 2493–6.
29. Campbell E. G., Gruen R. L., Mountford J., et al. A national survey of physician-industry relationships.N Engl J Med. 2007; 356: 1742–50.
30. Gagnon M.-A., Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 2008; 5: e1.
31. Harris G. As doctors write prescriptions, drug company writes a check. New York Times. 2004 June 27.
32. Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.
33. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000; 283: 373–80.
34. Ziegler M. G., Lew P., Singer B. C. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995; 273: 1296–8.
35. Steinman M. A., Harper G. M., Chren M. M., et al. Characteristics and impact of drug detailing for gabapentin. PLoS Med. 2007; 4: e134.
36. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004; 351: 1885–90.
37. Chren M. M., Landefeld C. S. Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994; 271: 684–9.
38. Orlowski J. P., Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest. 1992; 102: 270–3.
39. Morgan S. G., Bassett K. L., Wright J. M., et al. ‘Breakthrough’ drugs and growth in expenditure on prescription drugs in Canada. BMJ. 2005; 331: 815–6.
40. Johansen H. K., G?tzsche P. C. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999; 282: 1752–9.
41. J?rgensen K. J., Johansen H. K., G?tzsche P. C. Flaws in design, analysis and interpretation of Pfizer’s antifungal trials of voriconazole and uncritical subsequent quotations. Trials. 2006; 7: 3.
42. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981–97.
43. Lieberman J. A., Stroup T. S., McEvoy, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 1209–23.
44. Jones P. B., Barnes T. R., Davies L., et al. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006; 63: 1079–87.
45. Woo W. W. K., Man S.-Y., Lam P. K. W., et al. Randomized double-blind trial comparing oral paracetamol and oral nonsteroidal antiinfl ammatory drugs for treating pain after musculoskeletal injury. Ann Emerg Med. 2005; 46: 352–61.
46. Villanueva P., Peiry S., Librero J., et al. Accuracy of pharmaceutical advertisements in medical journals. Lancet. 2003; 361: 27–32.
47. Wilkes M. S., Doblin B. H., Shapiro M. F. Pharmaceutical advertisements in leading medical journals: experts’ assessments. Ann Intern Med. 1992; 116: 912–19.
48. J?rgensen A. W., Hilden J., G?tzsche P. C. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ. 2006; 333: 782–5.
49. Malhotra D. Pharmaceutical lies. BMJ. 2006 Oct 28.
50. Spurling G. K., Mansfield P. R., Montgomery B. D., et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: a systematic review. PLoS Med. 2010; 7: e1000352.
51. Bowman M. A., Pearle D. L. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988; 8: 13–20.
52. Bowman M. A. The impact of drug company funding on the content of continuing medical education. Mubius. 1986; 6: 66–9.
53. Can I buy you a dinner? Pharmaceutical companies increasingly use doctors’ talks as sales pitches. 2005 Aug. Available online at: www.worstpills.org (accessed August 2005).
54. Tramur M. R., Reynolds D. J., Moore R. A., et al. Impact of covert duplicate publication on metaanalysis: a case study. BMJ. 1997; 315: 635–40.
55. Aspinall R. L., Goodman N. W. Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials. BMJ. 1995; 311: 844–6.
56. Carlisle J., Stevenson C. A. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev. 2006; 3: CD004125.
57. Carlisle J. B. A meta-analysis of prevention of postoperative nausea and vomiting: randomized controlled trials by Fujii et al. compared with other authors. Anaesthesia. 2012; 67: 1076–90.
58. Does anesthesiology have a problem? Final version of report suggests Fujii will take retraction record, with 172. Retraction Watch. 2012 July 3.
59. Boseley S. Junket time in Munich for the medical profession – and it’s all on the drug firms. The Guardian. 2004 Oct 5.
60. Studdert D. M., Mello M. M., Brennan T. A. Financial confl icts of interest in physicians’ relationships with the pharmaceutical industry – self-regulation in the shadow of federal prosecution. N Engl J Med. 2004; 351: 1891–900.
61. Kassirer J. P. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
62. Smith R. The Trouble with Medical Journals. London: Royal Society of Medicine; 2006.
63. Heissel A. [‘The bomb’ has been defused]. Dagens Medicin. 2011 Feb 4.
64. Graudal N., J?rgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum. 2010; 62: 2852–63.
65. Tanne J. H. FDA approves prostate cancer ‘vaccine’ treatment. BMJ. 2012; 340: 998.
66. Hodi F. S., O’Day S. J., McDermott D. F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711–23.
67. Andersen N. V. [Drug with trivial effect]. Politiken. 2012 Feb 5.
68. Rasmussen L. I. [‘How can Henrik Dibbern believe that I have interests in the company?’] Ugeskr L?ger. 2012; 174: 248–9.
69. Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest. 2006; 116: 2837–42.
70. Sullivan R., Peppercorn J., Sikora K., et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011; 12: 933–80.
71. G?tzsche P. C., Johansen H. K. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev. 2010; 7: CD007851.
72. Jensen J. H., Korsgaard P. [We would drop chemotherapy and enjoy life]. Ekstra Bladet. 2012 March 16.
73. Dreier J. [Chemotherapy or not?]. Danish Cancer Society. 2012 March 19.
74. Slevin M. L., Stubbs L., Plant H. J., et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ. 1990; 300: 1458–60.
75. Watts G. Why the exclusion of older people from clinical research must stop. BMJ. 2012; 344: e3445.
76. Temel J. S., Greer J. A., Muzikansky A., et al. Early palliative care for patients with metastatic nonsmall-cell lung cancer. N Engl J Med. 2010; 363: 733–42.
77. Lenzer J. Spin doctors soft pedal data on antihypertensives. BMJ. 2003; 326: 170.
78. J?rhult B, Lindahl S.—O. [Doxazosin and heart failure: trustworthy information for patients’sake]. L?kartidningen. 2003; 48: 4011–12.
79. Fretheim A., Aaserud M., Oxman A. D. The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis. BMC Health Services Research. 2003; 3: 18.
80. Drachmann H., Andersen N. V. [Millions to spare on drugs]. Politiken. 2003 Dec 27.
81. Hagerup A. [Focus: drugs]. Ugeskr L?ger. 2009; 171: 203–5.
82. Lindberg M. [Interesting statements by Hans Ibsen and Novartis related to new rules for reimbursement of drugs]. Ugeskr L?ger. 2010; 172: 2476.
83. Ebdrup N. [Cheap antihypertensives equally good as expensive ones]. Videnskab.dk. 2012 April 13.
84. G?tzsche P. C. Reply. Ugeskr L?ger. 2011; 173: 599.
85. Boseley S. Concern over cancer group’s link to drug firm. The Guardian. 2006 Oct 18.
86. Coleman M. New drugs and survival: does the Karolinska report make sense? Cancer World. 2006 Sept—Oct: 26–35.
87. G?tzsche P. C. Mammography Screening: truth, lies and controversy. London: Radcliffe Publishing; 2012.
88. US Department of Justice. Danish pharmaceutical Novo Nordisk to pay $25 million to resolve allegations of off-label promotion of Novoseven. 2011 June 10.
89. Christenson S., Finley D. Drug fi rm’s wooing made whistleblower suspicious: Fort Sam doctor was early backer of medication to halt bleeding. San Antonio Express. 2011 June 26.
90. Boffard K. D., Riou B., Warren B., et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005; 59: 8–18.
91. Webert K. E., Blajchman M. A. Randomized trials in patients with blunt and penetrating trauma. J. Trauma. 2006; 60: 242–3.
92. Andersen N. V., Elles?e M. [Novo blockbuster buried]. Mandag Morgen. 2008; 27: 9–13.
93. Tedesco J. Military medicine scheme is alleged: S. A. nonprofit tied to alleged scam to influence decisions by doctors. San Antonio Express. 2011 July 20.
94. Mogensen T. [Who is guarding the guardian?]. Ugeskr L?ger. 2008; 170: 3076.